Fresenius Acquires APP Pharmaceuticals (APPX) For $23/Share, Plus An Extra $6 If Results are Meet
APP Pharmaceuticals, Inc. (Nasdaq: APPX) and Fresenius SE (XETRA: FRE) entered into a definitive merger agreement pursuant to which Fresenius will acquire APP.
Under the terms of the agreement, Fresenius will acquire the outstanding common stock of APP for $23.00 in cash per share plus a contingent value right that could deliver up to an additional $970 million, or $6.00 per share in cash, if the financial results of the Company meet certain targets.
APP Pharmaceuticals closed at $17.82 on Friday.
Under the terms of the agreement, Fresenius will acquire the outstanding common stock of APP for $23.00 in cash per share plus a contingent value right that could deliver up to an additional $970 million, or $6.00 per share in cash, if the financial results of the Company meet certain targets.
APP Pharmaceuticals closed at $17.82 on Friday.
You May Also Be Interested In
- UPDATE: Angelo, Gordon to Acquire Benihana (BNHN) for $16.30/Share in Cash
- Wal-Mart Stores (WMT) Reports Solid Q1, Comps Up 2.6%; Offers Q2 Outlook
- DigitalGlobe (DGI) Pops On Rumors of Higher Bid
Create E-mail Alert Related Categories
Hot List, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
